Literature DB >> 16827960

Dacryocystorhinostomy without intubation with intraoperative mitomycin-C.

Azizur Rahman1, Shahnawaz Channa, Jawaid Hassan Niazi, Muhammad Saleh Memon.   

Abstract

OBJECTIVE: To evaluate the success rate and complications of intraoperative Mitomycin-C in dacryocystorhinostomy (DCR) surgery. STUDY
DESIGN: Quasi-experimental study. PLACE AND DURATION OF STUDY: Isra postgraduate institute of Ophthalmology, Al-Ibrahim Eye Hospital, Malir, Karachi, from January 2003 to December 2004. PATIENTS AND METHODS: This study included total 90 eyes of 90 patients fulfilling the inclusion criteria. The surgical procedure of external DCR done with intraoperative Mitomycin-C with a neurosurgical cottonoid soaked with 0.2 mg/ml. Mitomycin C was applied to the anastomosed flaps and osteotomy site for 10 minutes, without Silicon tube intubation. Surgery was done under local as well as general anesthesia. Patients were followed for 6 months.
RESULTS: Out of 90 patients included in this study, only 2 patients complained of persistent epiphora after 6 months follow-up and were labeled as failed DCR. Remaining 88 had either no tearing or significant improvement of tearing after 6 months follow up and patent lacrimal system by syringing without pressure. Success rate in this procedure was 97.77% (p-value < 0.001). This study showed very high rate of success. Only complication noted was excessive nasal bleeding which was easily controlled.
CONCLUSION: Intraoperative Mitomycin-C application in external DCR is safe, effective, cheap adjunct that helps to achieve good results of DCR surgery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16827960     DOI: 7.2006/JCPSP.476478

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  1 in total

Review 1.  [Current status of dacryocystorhinostomy].

Authors:  H-W Meyer-Rüsenberg; S Vujancevic; K-H Emmerich
Journal:  Ophthalmologe       Date:  2009-03       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.